Benitec Biopharma Inc.
Close on Oct 19, 2026
- Market cap
- $413.29M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Sep 14, 2026 | After market close | – | – | – |
| Q3 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | $-0.24 | – |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | – | $-0.26 | – |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | – | $-0.22 | – |
| Q4 FY2025 Ended Jun 30, 2025 | Sep 22, 2025 | After market close | – | – | – |
| Q3 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | $-0.24 | – |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 14, 2025 | Before market open | $0 | $-0.33 | – |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $0 | $-0.48 | – |
| Q4 FY2024 Ended Jun 30, 2024 | Sep 26, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | $0 | $-1.64 | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 13, 2024 | Before market open | $0 | $-2.64 | – |
Press releases
Announcements Benitec Biopharma filed with the SEC
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Regulation FD disclosure · EX-99.1 to Form 8-K
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Benitec Biopharma Announces Appointment of
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Positive Clinical Data Supporting Advancement of BB-301 in OPMD WEBCAST: November 3, 2025 ©2025 Benitec Biopharma. All rights reserved. OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) A Debilitating, Progressive Disease With No Approved Therapies NASDAQ BNTC
Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Provides Operational Updates
Regulation FD disclosure · EX-99.1 to Form 8-K
HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) Benitec Biopharma Inc. (NASDAQ: BNTC) (Benitec
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301
Regulation FD disclosure · EX-99.1 to Form 8-K
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29 th Annual Congress of the World Muscle Society
Regulation FD disclosure · EX-99.1 to Form 8-K
540 Madison Ave., 7 th Floor
Other events · EX-99.1 to Form 8-K
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing
Regulation FD disclosure · EX-99.1 to Form 8-K
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Regulation FD disclosure · EX-99.1 to Form 8-K
©2024 Benitec Biopharma | All Rights Reserved
Regulation FD disclosure · EX-99.2 to Form 8-K
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Announces First Subject Dosed in Phase
Regulation FD disclosure · EX-99.1 to Form 8-K
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Releases Full Year 2023
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Benitec Biopharma Announces 1-for-17 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal
Regulation FD disclosure · EX-99.1 to Form 8-K
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Benitec Biopharma Releases First Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Benitec Biopharma Releases Q3 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K